56 results about "Egg phospholipids" patented technology

The invention discloses a lipophilic liposome containing polydeoxyribonucleotide as well as a preparation method and application of the lipophilic liposome. The lipophilic liposome comprises the following components in parts by weight: 0.001-3 parts of polydeoxyribonucleotide; 0.5 to 3 parts of phospholipid; 0.1-2 parts of a cationic emulsifier; 0.1-3 parts of an anionic emulsifier; 40 to 70 parts of polyol; the total amount is 100 parts. According to the invention, an emulsifier system formed by combining lecithin with anionic and cationic compound surfactants is adopted, so that the transdermal absorption of PDRN is facilitated. The lipophilic liposome containing polydeoxyribonucleotide prepared by the invention can effectively resist nuclease degradation, prolong the acting time of PDRN in skin, and improve the skin anti-aging and repairing effects of the liposome. The anti-aging effect of the active ingredients is improved, and the bioavailability of the active ingredients is improved. The cosmetic composition can be widely applied to cosmetic formulas of various dosage forms.

The invention relates to a novel camellia saponin derivative feed additive and a preparation method thereof, and belongs to the technical field of feed additives. The modified chitosan is used in the flocculation and impurity removal process for preparing the camellia oleifera saponin derivative, and the modified chitosan reduces the loss of effective components caused by flocculation and impurity removal while ensuring the purity of the camellia oleifera saponin derivative; soybean lecithin and gelatin are used as capsule walls, the camellia saponin derivative and pyropheophorbide-a are wrapped, pyropheophorbide-a can generate singlet oxygen under excitation of visible light, phospholipid bonds are damaged, the camellia saponin derivative is released, and therefore the slow release effect is achieved; the novel camellia saponin derivative feed additive prepared by the invention has good antibacterial property and timeliness.

The invention provides ROS (reactive oxygen species)-responsive cationic liposome-loaded tryptanthrin as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The ROS response cationic liposome loaded tryptanthrin disclosed by the invention comprises an ROS response cationic liposome and tryptanthrin which is entrapped in the ROS response cationic liposome; the ROS response cationic liposome is prepared from the following raw materials: egg yolk lecithin, cholesterol, DSPE-TK-PEG (distearoyl phosphatidylcholine) and DOTAP (dioctyl phthalate). In view of significant increase of intestinal local active oxygen under the ECLS condition, the ROS-responsive cationic liposome is adopted to wrap tryptanthrin, so that tryptanthrin is selectively released in an intestinal injury area, whole body exposure is reduced, and meanwhile, the protection effect on the intestinal tract is enhanced.

The present invention provides a nutritional composition comprising milk phospholipids and egg phospholipids, particularly suitable as a nutritional composition for infants, also as a nutritional support product for pregnant women and as a nutritional supplement for the elderly, in which phosphatidylcholine and sphingomyelin and hence choline are also highly correlated. The invention provides a nutritional composition containing choline with high bioavailability.

This invention relates to the field of asiaticoside technology, and discloses asiaticoside liposome compositions, preparation methods, and applications. Specifically, based on molecular design principles, monoprotonated tertiary amine permeation enhancers and diprotonated tertiary amine permeation enhancers are synthesized. Using egg yolk lecithin, cholesterol, monoprotonated or diprotonated tertiary amine permeation enhancers, and asiaticoside as raw materials, asiaticoside liposome compositions are prepared by thin-film dispersion. The liposome composition exhibits a transdermal permeability of >90% after 48 hours, demonstrating excellent transdermal performance, and also possesses excellent encapsulation and drug loading properties, making it suitable for preparing gel formulations for treating skin lesions.

The invention discloses a soybean protein-phospholipid biomimetic membrane as well as a preparation method and application thereof. The biomimetic membrane is formed by three raw materials of soybean protein, soybean lecithin and a charged polymer through electrostatic interaction and a physical blending method. The soybean 11s protein solution, the lipidosome dispersion liquid and the charged polymer solution are mixed to obtain the mosaic structure biomimetic membrane which is formed by combining various chemical bond crosslinking and electrostatic interaction, and the process conditions are simple, efficient, convenient and environmentally friendly. The biomimetic membrane provided by the invention has a mosaic structure and the characteristics of the raw materials, so that the biomimetic membrane has high ion passing rate, strong ion selection capability, excellent monovalent cation and divalent cation separation capability and certain biodegradability. When the biomimetic membrane is applied to ion separation, the separation capacity of ions with different valence states can be effectively improved, the separation effect of sodium ions and magnesium ions is optimal, and the separation factor is as high as 21.28 and is 54.6 times that of a biomimetic membrane without charges.

The present invention provides a nutritional composition especially well suited as an infant nutritional composition, but also as a nutritional support product for pregnant women and as senior nutritional supplement, where phosphatidylcholine and sphingomyelin, and thus choline, also are highly relevant. The present invention provides a nutritional composition which contains choline of high bio-availability.

The application relates to the field of biological medicine, and discloses ascorbyl palmitate nanoliposomes capable of inducing tumor cell oncosis, a preparation method and application thereof. The nanoliposomes are constructed by inserting ascorbyl palmitate as a lipid component into a phospholipid bilayer, and are prepared by a film dispersion method from lecithin, cholesterol, pegylated phospholipid and ascorbyl palmitate. The average particle size of the nanoliposomes is 80-150 nm, the encapsulation rate is high, and the stability is good. The nanoliposomes can be administered through a tail vein, utilize the specific hydrolysis of matrix metalloproteinase MMP-2 which is highly expressed by tumor cells to hydrolyze ascorbyl palmitate, release palmitic acid and ascorbic acid, thereby inducing Caspase-independent oncosis of tumor cells, effectively overcoming apoptosis-related drug resistance, and reversing a tumor immunosuppressive microenvironment. The nanoliposomes avoid the cumulative toxicity of metal-type inducers, and provide a new safe and effective option for reversing chemotherapy resistance.

A process for producing a triglyceride-phospholipid concentrate is provided, the process comprising: providing an egg yolk lecithin solution from the extraction of an egg yolk material with a liquid extractant, mixing the egg yolk lecithin solution with an OPO triglyceride carrier comprising 1,3-dioleoyl-2-palmitoylglycerol and having a ratio of palmitic acid in the 2-position of the triglycerides relative to the total palmitic acid in the triglycerides (SN2-C16:0) of at least 50%, and a C52 triglyceride content of at least 42 wt.%, and separating the liquid extractant from the mixture to produce a triglyceride- phospholipid concentrate comprising the OPO triglyceride carrier and egg lecithin.

The application belongs to the field of biological medicine, and discloses a nano-lipid preparation for loading perfluorohexane and an antioxidant, wherein the nano-lipid preparation is a core-shell structure, the core-shell structure takes a phospholipid liposome membrane layer as an outer shell, and perfluorohexane and the antioxidant loaded in the outer shell serve as an inner core; the phospholipid liposome membrane layer is made of hydrogenated lecithin, distearoyl phosphatidyl ethanolamine-polyethylene glycol 2000 and cholesterol; and the application discloses an application of the nano-lipid preparation for loading perfluorohexane and the antioxidant in preparation of a medicine for treating myocardial infarction. The nano-lipid preparation has a suitable particle size, can be passively targeted and enriched to a myocardial infarction site, is stable, has a high encapsulation efficiency, and has a simple administration mode; after the lipid preparation is taken by myocardial cells, oxygen and the antioxidant are released, the oxygen can relieve an anoxic condition of a myocardial ischemia site, and the antioxidant can reduce ROS damage, both of which play a synergistic role, improve the survival rate of ischemic myocardial cells, and improve heart function.

The invention provides a high-stability blueberry anthocyanin polycystic liposome and a preparation method of the high-stability blueberry anthocyanin polycystic liposome. The preparation raw materials comprise 5 to 12 parts of a pH response type phospholipid derivative, 3 to 8 parts of mesoporous silica-polydopamine hybrid nanoparticles, 28 to 42 parts of egg yolk lecithin, 8 to 12 parts of cholesterol, 5 to 9 parts of glyceryl trioleate, 2 to 5 parts of vitamin E succinate, 10 to 18 parts of a citric acid-malic acid buffer solution, 45 to 85 parts of trehalose, 16 to 32 parts of a Tween 80-Arabic gum compound, 4 to 8 parts of chitosan quaternary ammonium salt and 5 to 13 parts of polyethylene glycol-2000. 160-280 parts of ultrapure water and 6-22 parts of blueberry anthocyanin. The blueberry anthocyanin polycystic liposome disclosed by the invention has high encapsulation efficiency, excellent photo-thermal stability and long-term storage stability.

The invention relates to the field of biological medicine, and provides an HDAC inhibitor coated liposome degradation agent, which comprises hydrogenated lecithin, cholesterol, an HDAC inhibitor, targeted EGFR drug modified functional phospholipid and E3 ligase ligand modified functional phospholipid. The invention further provides a preparation method of the liposome degradation agent wrapping the HDAC inhibitor and application of the liposome degradation agent in preparation of antitumor drugs. The EGFR-targeted liposome degradation agent is combined with the HDAC inhibitor, malignant proliferation of the osimertinib-resistant non-small cell lung cancer is synergistically overcome from multiple channels, and a new treatment thought is expected to be provided for clinical osimertinib-resistant lung cancer patients.

The invention relates to the technical field of madecassoside, and discloses a madecassoside liposome composition as well as a preparation method and application thereof, specifically, based on a molecular design principle, a monoprotonated tertiary amine penetration enhancer and a diprotonated tertiary amine penetration enhancer are synthesized; yolk lecithin, cholesterol, a monoprotonated tertiary amine penetration enhancer or a diprotonated tertiary amine penetration enhancer and madecassoside are used as raw materials, the madecassoside lipidosome composition is prepared through a film dispersion method, and the transdermal rate of the lipidosome composition after 48 hours is gt; according to the present invention, the prepared hydrogel has excellent transdermal performance, excellent encapsulation performance and excellent drug loading performance, and can be used for preparing a gel preparation for treating skin injury.

The invention provides a niclosamide and chlorine e6 co-loaded liposome. The niclosamide and chlorine e6 co-loaded liposome is prepared from the following components in parts by weight: 150 to 250 parts of egg yolk lecithin, 5 to 15 parts of cholesterol, 1 to 5 parts of niclosamide, 1 to 5 parts of chlorine e6, 15 to 25 parts of DSPE-SS-MPEG2K and 5 to 20 parts of polyvinyl alcohol. The preparation method is simple to operate and mild in reaction condition. The prepared lipidosome is uniform in particle size, good in water solubility, good in biological safety and high in drug loading capacity, due to introduction of DSPE-SS-MPEG2K, the lipidosome has the glutathione (GSH) response characteristic, not only keeps stable in a normal physiological environment, but also can trigger disulfide bond breakage under the condition of high-concentration GSH in a tumor microenvironment, fixed-point quick release of drugs is achieved, and the application prospect is wide. The breast cancer treatment capability is synergistically enhanced.

The invention discloses a drug-loaded liposome constructed on the basis of saikoside D, and a preparation method and application of the drug-loaded liposome. The liposome comprises soybean lecithin, saikoside D, phosphatidic acid, an active drug and poloxamer 407. According to the invention, the saikosaponin D with antitumor activity is used for completely replacing cholesterol in the traditional liposome, so that the potential health risk of the cholesterol is avoided, the integration of medicines and auxiliary medicines is realized, and the saikosaponin D and entrapped medicines can generate a synergistic antitumor effect. The modification of the poloxamer 407 endows the liposome with the long circulation characteristic. The preparation method adopts a film dispersion-ultrasonic method, and is simple and convenient to operate. The prepared lipidosome is small in particle size, narrow in distribution and good in stability, the drug loading capacity is about 1.5-7.0%, the tumor cell inhibition effect superior to that of traditional cholesterol lipidosome and free drugs is shown in vitro, and the lipidosome has wide application prospects in the aspect of preparation of anti-tumor drugs.

The application relates to the technical field of pharmacy, in particular to a kind of lipid nanoparticles and a preparation method and application thereof.The lipid nanoparticles include nano-phospholipid disc and IMB-AL0912;The nano-phospholipid disc includes lung mucus component phospholipid, negative electric phospholipid, yolk lecithin and 4F peptide;The mass ratio of 4F peptide and lung mucus component phospholipid is 1: (5-10) in terms of mass ratio.A new kind of lipid nanoparticle is obtained by improving nano-phospholipid disc loading polymyxin antibiotic IMB-AL0912, the lipid nanoparticle has the effect of significantly reducing cell damage and inflammatory factor expression caused by LPS stimulation, has a significantly better prevention and treatment effect on bacterial infection and sepsis, is lower in toxicity, and has a wider clinical application range.

This invention discloses a photosynthetic nanomotor powered by a biomolecular motor and its preparation method, belonging to the field of colloidal motors. This invention aims to address the current limitations of research on the rotational dynamics of FoF1-ATP synthase molecular machines, which is limited to the motion of single and isolated objects. The photosynthetic nanomotor is prepared based on supramolecular self-assembly technology through the reconstruction of thylakoid vesicles and lecithin vesicles. The photophosphorylation system on the thylakoid membrane surface is reconstructed on the photosynthetic nanomotor. Utilizing the preserved biomolecular motor FoF1-ATPase as the power engine, under external visible light irradiation, protons generated by the photosystem accumulate in the photosynthetic liposome motor, driving the FoF1-ATPase to synthesize the energy currency ATP. Through metabolic reactions, light energy is converted into chemical energy ATP, ultimately generating self-propulsion. Due to its unique energy currency regeneration capability, the photosynthetic liposome motor has broad application prospects in the biomedical field.

An adjuvant composition comprising lecithin and an organosilicon surfactant as defined herein.

The invention provides a method for identifying pure euphausia superba oil, which comprises the following five steps of: arranging layer-by-layer filtering fences by using sensory evaluation, physical and chemical indexes and nuclear magnetic resonance spectrum of marine food euphausia superba oil, identifying adulterated samples such as fish oil, vegetable oil, soybean phospholipid, egg phospholipid and the like, and realizing pure euphausia superba oil identification. The method is simple to operate and relatively low in cost, the identified pure euphausia superba oil is reliable in quality and relatively high in additional value, and meanwhile, the defect of lack of true and false identification of the euphausia superba oil at present is overcome.

The invention discloses an RVG29 modified ziconotide loaded liposome as well as a preparation method and application thereof. The nano-liposome is prepared from phosphatidylpolyethylene glycol-RVG29, lecithin, cholesterol, phosphatidic acid and ziconotide. The preparation method comprises the following steps: performing repeated washing, resin detection and condensation operation on 2-chlorotrityl chloride resin and the like to prepare RVG29 resin, performing cutting sedimentation treatment and high performance liquid chromatography purification on the RVG29 resin by using phospholipid-polyethylene glycol-active ester and a cutting reagent, and adding lecithin, cholesterol, phosphatidic acid and ziconotide to synthesize and prepare the product liposome. The nano-liposome is a novel nano-liposome for the nose and the brain, gel adhesion and drug delivery are improved, the surface of the liposome targets a nicotinic acetylcholine receptor on the surface of a neuron, accurate drug delivery is achieved, no small-molecule cytotoxic drugs participate in the nano-liposome, the treatment compliance of cancer pain patients is improved, and the nano-liposome is a novel nano-liposome for the nose and the brain. The treatment effect and the life quality are improved.

A method for reducing a subcutaneous fat deposit or a visceral fat deposit in vivo by contacting the fat deposit with a composition of latanoprost encapsulated in a liposome formed solely of egg phosphatidylcholine (EggPC) or palmitoyloleoyl phosphatidylcholine (POPC). Also disclosed are methods for treating steatoblepharon, proptosis, and obstructive sleep apnea associated with excess upper airway fat by injecting into the eyelid, intraconal space, and upper airway fat deposit, respectively, the composition of latanoprost encapsulated in an EggPC or POPC liposome.

The invention belongs to the technical field of biological medicine, and provides a liposome nano lysosome degradation agent for targeting LRG1 as well as a preparation method and application thereof, and the liposome nano lysosome degradation agent is composed of egg yolk lecithin / cholesterol nano liposome, entrapped GYY4137, LRG1 targeting ET polypeptide with the surface subjected to click chemical modification and a lysosome targeting M6P ligand. A microfluidic technology is adopted for preparation, the molar ratio of DSPE-PEG2000-ET to DSPE-PEG2000-M6P is 1: 3, and the mass ratio of lipid to a medicine is 2: 1. The degradation agent can be used for accurately activating hepatic stellate cells in a targeted manner, guiding LRG1 to enter lysosome for degradation and cooperating with GYY4137 for release, so that a dual anti-hepatic fibrosis effect is realized, and the degradation agent is used for preparing medicines for treating hepatic diseases such as hepatic fibrosis.

The application discloses a ROS-targeted nano-drug delivery system, which uses a biomimetic hybrid nanovesicle and montmorillonite as a composite carrier and loads ROS-responsive micelles prepared by mixing a PD-L1 antagonistic peptide complex and an RGD complex. The biomimetic hybrid nanovesicle is prepared by modifying a cell-derived nanovesicle with a liposome composed of lecithin, cholesterol and rhamnolipid. The system realizes the synergy of four functions through the EPR effect of the biomimetic hybrid nanovesicle, the active targeting of RGD, the immunomodulation of the PD-L1 antagonistic peptide and the ROS-responsive rupture of the micelles. Experiments show that the system has a significant structural response under a high ROS environment, can quickly disintegrate to release drugs, has high selectivity and high uptake rate for high-ROS tumor cells, has low toxicity to normal cells and good blood compatibility. The system provides an efficient and safe nano-drug delivery platform for the targeted treatment of ROS-related diseases such as tumors.

The present application relates to a kind of egg-laying hens premix with DHA efficient enrichment and egg preservation, and application thereof, belong to animal nutrition and feed technology field.The present application first clearly that phospholipid deficiency is the core reason of limiting DHA enrichment efficiency, reveals that soy lecithin promotes the molecular mechanism of DHA deposition by up-regulating FABP, PCTP expression, and proves that astaxanthin through direct free radical scavenging and the double synergistic antioxidant mechanism of activating endogenous antioxidant enzyme system.Based on this, with microencapsulated schizochytrium sp powder, high-purity soy lecithin, astaxanthin as core component, compound probiotics, lutein, organic selenium, construct four-effect synergistic premix formula, and establish "DHA enrichment-egg quality-shelf life" linkage parameter system.Application of the present application, egg DHA enrichment amount reaches 500~1000 mg / 100 g yolk, feeding 2 weeks stable enrichment, egg production rate keeps more than 85%, shelf life is extended by 15~20 days, with efficient nutrition fortification and preservation function.

The invention belongs to the technical field of specific therapeutic activity of compounds or pharmaceutical preparations, and particularly relates to a cordycepin nano-liposome, preparation and application of the cordycepin nano-liposome in treatment of lung injury. The cordycepin nano-liposome provided by the invention is composed of cordycepin, lecithin, cholesterol, dipalmitoyl phosphatidylcholine-polyethylene glycol and water-soluble pentosan, is prepared by adopting a film hydration method, and has high drug loading capacity, high bioavailability and excellent physical stability; precise lung targeted delivery is achieved by means of the synergistic effect of the components, and in-vivo experiments prove that the nano-liposome can effectively inhibit inflammatory response of the acute lung injury part and remarkably improve the lung injury symptom, provides an efficient treatment scheme for acute lung injury, and has important clinical transformation value and wide application prospects.

This invention discloses a magnetic drug-loaded liposome for nerve repair and its preparation method. The magnetic drug-loaded liposome prepared by this method contains magnetic nanoparticles and a drug. The mass fractions of egg yolk lecithin, cholesterol, DSPE-MPEG 2000, BFe3O4, and the drug in 1 mL of the liposome solution are 0.5%–1.5%, 0.15%–0.35%, 0.1%–0.35%, 0.1%–0.2%, and 0.1%–0.2%, respectively. The drug is one or more of the natural antioxidants such as piracetamine, resveratrol, or tea polyphenols. The multifunctional magnetic drug-loaded liposome provided by this invention, combined with magnetic field loading, can be used for the repair of damaged nerve cells.

The application relates to a pH-sensitive phospholipid-modified nattokinase magnetic-targeting nano-drug liposome and a preparation method thereof. In the application, egg yolk lecithin is selected as basic material of a phospholipid bilayer, DSPE-PEOz2000 is selected as a pH-sensitive material, and magnetic ferroferric oxide nanoparticles are selected as magnetic material. The system is based on pH-sensitive liposomes, and the water phase is loaded with thrombolytic drugs nattokinase and citric acid-modified ferroferric oxide nanoparticles. Compared with traditional drugs, the drug-loaded system can release the drugs at a specific site, maintain the enzyme activity of nattokinase, realize the targeted delivery of thrombolytic drugs, and achieve better thrombolytic effect.

The invention provides a pharmaceutical composition containing PROTAC small molecules and siRNA molecules and application of the pharmaceutical composition, and belongs to the technical field of preparation of alopecia drugs. The invention provides a composition formed by siRNA containing a targeted NFKBIZ gene and functional small molecules (protein degradation targeted chimera molecules or fish-derived peptide LAGF molecules) with targeted degradation of an androgen receptor (AR), and nanoparticles prepared by using a soybean lecithin nano-liposome delivery system can effectively overcome the difficulty of delivery of the composition to keratinocytes. Compared with the prior art, the composition provided by the invention has the advantages of promoting efficient skin delivery, removing excessive ROS (reactive oxygen species), inhibiting inflammatory response in hair follicles, providing an effective multi-target strategy for AGA treatment, effectively down-regulating the expression of AR protein, regulating a signal channel related to hair growth, and finally realizing multi-mode synergistic treatment on AGA, thereby enhancing the treatment effect on alopecia.

The application discloses a folate-chicoric acid liposome for treating ulcerative colitis and a preparation and application thereof, and relates to the technical field of veterinary drugs. The folate-chicoric acid liposome is composed of egg yolk lecithin, cholesterol, chicoric acid and folate (mass ratio of 10-14:2-5:1-2:1-2), has targeting property, has the effect of targeting macrophages, inhibits the polarization of macrophages to M1 type, can improve the clinical symptoms (weight loss, hematochezia and the like) of ulcerative colitis mice, increase the colon length, reduce the DAI score, the CMDI score and the colon index, relieve the pathological damage of the colon and relieve intestinal inflammation. The liposome has the effect of treating ulcerative colitis mice, and can provide an efficient drug for treating ulcerative colitis in the livestock breeding industry. Meanwhile, the liposome has the advantages of simple preparation method, good treatment effect, high specificity, safety and non-toxicity.